Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
- Conditions
- Interventions
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00589784
- Locations
- 🇺🇸
University of Virginia Health Science Center, Charlottesville, Virginia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States
Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers
- First Posted Date
- 2007-12-31
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 23
- Registration Number
- NCT00583063
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
- Conditions
- Interventions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 52
- Registration Number
- NCT00577382
- Locations
- 🇺🇸
Washington University in St. Louis, St. Louis, Missouri, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
- Conditions
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00573404
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
Brain Mets - Capecitabine Plus Sunitinib and WBRT
- Conditions
- Interventions
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Baylor Breast Care Center
- Target Recruit Count
- 12
- Registration Number
- NCT00570908
- Locations
- 🇺🇸
Lester and Sue Smith Breast Center at Baylor College of Medicine, Houston, Texas, United States
Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT00556205
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT00556049
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center', Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT00555672
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-11-08
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT00555620
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT00553696
- Locations
- 🇯🇵
Saku Central Hospital, GI Devision, Saku, Nagano, Japan
🇯🇵Aichi cancer center central hospital / Medical Oncology, Nagoya, Aichi, Japan
🇯🇵Shizuoka Cancer Center, Suntougun, Shizuoka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.